Business
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®
HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy Preclinical data suggest
About this update from Arbutus Biopharma Corporation
[{"type":"text","content":"HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy Preclinical data suggest that AB-101, an oral PD-L1 inhibitor, in combination with an RNAi, may provide enhanced HBV immune response Data to be presented as poster presentations Additional safety findings lead to discontinuation of AB-836 development Conference call and webcast scheduled for Friday, November 4th at 8:45 AM ET WARMINSTER, Pa., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced data from i) two separate clinical trials evaluating its RNAi therapeutic, AB-729, in a Phase 1a/1b clinical trial (AB-729-001) and in a combination Phase 2a clinical trial with a capsid inhibitor, and ii) a preclinical study of its oral PD-L1 inhibitor, AB-101. All of the data will be presented as poster presentations at AASLD – The Liver Meeting being held in Washington, DC, November 4-8, 2022. “Based on the compilation of safety and efficacy data achieved to-date, we are confident in AB-729’s potential role as a cornerstone agent in a curative combination treatment for chronic hepatitis B virus infection (cHBV), said William Collier, Arbutus’ President and Chief Executive Officer. “We believe AB-729 is the only RNAi therapeutic in development for hepatitis B virus that has clinically shown its ability to suppress HBV DNA, reduce HBsAg and immunologically control HBV – three pillars that we consider to be key to developing a functional cure for HBV.” AB-729-001 Clinical Trial Data In the AB-729-001 clinical trial, patients with cHBV who completed 48 weeks of treatment with AB-729, and 24 weeks later met protocol-defined criteria to also stop nucleos(t)ide analogue (NA) therapy, were evaluated during an extended follow-up period to assess HBV biomarkers and ALT levels. Nine patients entered the follow-up period, currently ranging from 12 to 44 weeks, after stopping all therapies. Select key findings: No evidence of clinical/biochemical relapse has been detected in the nine patients who have discontinued AB-729 and NA therapy.HBsAg remains at 1.05 to 2.35 log10 below pre-trial levels in all nine patients.Three pati...